Reminder: Roche’s virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting Montag, 07. Februar 2022 - 15:18

We are pleased to invite investors and analysts to participate in our virtual event on Monday,
14 February 2022, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2022 Meeting, from 11th to 12th February.

16:30 – 17:45 CET / 15:30 - 16:45 GMT

10:30 – 11:45 am EST / 7:30 – 8:45 am PST

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.
> click here

Agenda

Ophthalmology franchise strategy
Nilesh Mehta, Global Franchise Head, Ophthalmology

Ophthalmology clinical development
Christopher Brittain, Vice President and Global Head of Ophthalmology Product Development

Angiogenesis highlights
2-Year data for Susvimo in nAMD (Ph III Archway)
2-Year data for Vabysmo in DME (Ph III YOSEMITE & RHINE)
Nancy Holekamp, M.D., Retina Specialist

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Sabine Borngräber

Investor Relations Officer

Roche Investor Relations

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com